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Krüppel-like factor 5 (KLF5) is known to physically interact with retinoic acid receptor-a (RARa).
Here, we show that Am80 inhibited the interaction between KLF5 and RARa and this inhibitory
effect was accompanied by the dephosphorylation of KLF5 in VSMCs. Treating VSMCs with
LY294002, the PI3K/Akt inhibitor, abrogated Am80-induced KLF5 dephosphorylation and reversed
Am80-induced suppression of interaction between KLF5 and RARa, whereas treating vascular
smooth muscle cells (VSMCs) with SB203580, the p38 kinase inhibitor, attenuated the interaction
between KLF5 and RARa. Constitutively active p38 kinase MKK6b infection prevented the KLF5
dephosphorylation induced by Am80. In conclusion, Am80 induces KLF5 dephosphorylation by acti-
vating PI3K/Akt signaling, and inhibits KLF5 phosphorylation by blocking p38 signaling, subse-
quently leading to the suppression of interaction of KLF5 with RARa.
Structured summary:
MINT-7013243: Klf5 (uniprotkb:Q66HP1) physically interacts (MI:0218) with RAR alpha (uni-
protkb:Q9QWJ1) by anti bait coimmunoprecipitation (MI:0006)
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Krüppel-like factors (KLFs) belong to the transcription factor
family containing zinc-ﬁnger structures, mainly involved in regu-
lating cell growth, differentiation, proliferation and apoptosis, by
controlling the expression of a large number of genes with GC/
GT-rich promoters [1,2]. As one of this family, KLF5 (IKLF, BTEB2)
was identiﬁed as a pro-proliferative regulator [3]. KLF5 has
growth-promoting functions in a variety of cell types through its
activation of key cell-cycle-promoting genes [4–6]. In addition to
its pro-proliferative role, KLF5 is implicated in injury response
pathways as well as the activation of inﬂammatory pathways fol-
lowing exposure to inﬂammatory stimuli. KLF5 is abundantly ex-
pressed in embryonic vascular smooth muscle cells (VSMCs) and
is downregulated with vascular development. However, KLF5on behalf of the Federation of Euro
dimethyl sulfoxide; FBS, fetal
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n activator inhibitor-1; PI3K,
tor-a; VEGF, vascular endo-
e cellsexpression can be re-induced in adult VSMCs after vascular injury
and can activate many genes inducible during cardiovascular
remodeling, such as PDGF-A/B, Egr-1, plasminogen activator inhib-
itor-1 (PAI-1), inducible NO synthase (iNOS), and vascular endo-
thelial growth factor (VEGF) receptors [7]. Importantly, KLF5 (+/
) mice exhibit a marked reduction in neointima formation and
VSMC proliferation following vascular injury [8], whereas forced
overexpression of KLF5 can promote cellular proliferation and
can induce expression of PDGF-A/B, PAI-1, Egr-1, iNOS, and VEGF
receptors. These results indicate that KLF5 is an important regula-
tor of VSMC response to vascular injury and can critically regulate
vascular remodeling.
Given the importance of KLF5 in cardiovascular remodeling,
control of its activity has been the subject of considerable investi-
gation. Indeed, several studies have shown that KLF5 activities are
regulated by a variety of transcriptional regulators and nuclear
receptors, such as retinoic acid receptor-a (RARa). Importantly,
Shindo and colleagues demonstrated that KLF5 interacts with
RARa [8,9]. We and others have previously shown that all-trans
retinoic acid (ATRA) can induce differentiation and inhibit prolifer-
ation, and cell migration of VSMCs as well as suppress neointima
formation and restenosis after balloon injury. Additionally, Am80,
a synthetic RARa-speciﬁc agonist, can prevent in-stent neointimapean Biochemical Societies.
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governed by the activity of a regulator network [10,11], we predict
that functional interactions between pro-proliferation factors, such
as KLF5 [8], and pro-differentiation factors, such as RAR [12], may
modulate such a network and determine cellular functions.
Although several lines of evidence suggest that Am80 inhibits the
interaction between KLF5 and RARa, the molecular mechanisms
of action of Am80 in VSMCs are not fully understood.
In the present study, we analyzed the mechanism by which
Am80 inhibits the interaction between KLF5 and RARa, and dem-
onstrated that Am80 rapidly induces KLF5 dephosphorylation in
rat VSMCs. Moreover, PI3K/Akt, which is activated after Am80
treatment, mediates KLF5 dephosphorylation, and p38, which is
inhibited after Am80 treatment, mediates KLF5 phosphorylation,
subsequently leading to the inhibition of the interaction between
KLF5 and RARa.
2. Materials and methods
2.1. Cell culture and treatment
VSMCs were isolated from the thoracic aorta of 90–100 g male
Sprague–Dawley rats as previously described [13]. VSMCs were
maintained and passaged in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Hy-
Clone), 100 U/ml penicillin, and 100 lg/ml streptomycin. In all
experiments, only cell passages 3–5 were used. All experiments
were initiated when the cells reached 70% conﬂuence, except if sta-
ted otherwise. Cultured VSMCs were growth-arrested by incuba-
tion in serum-free DMEM for 24 h and then stimulated by Am80
(Osaka) as indicated. For the inhibitor studies, cells were pre-
treated with inhibitors LY294002 (Promega) or SB203580 (Prome-
ga) in dimethyl sulfoxide (DMSO) for 2 h before the application of
Am80 (2 lmol/L).
2.2. Plasmid and transfection
Constitutively active MAPK kinase MKK6b was kindly provided
by Dr. Han J (The Scripps Research Institute, California) [14]. PMT-
KLF5 plasmid was kindly provided by Dr. Mandayam N (Emory
University, Georgia). Mutation of KLF5 S406 to A (KLF5 S406A)
and KLF5 S432 to A (KLF5 S432A) was carried out using the Quik-
Change site-directed mutagenesis kit (Stratagene) according to the
manufacturer’s instructions. Each mutation was veriﬁed by DNA
sequence analysis. VSMCs were transfected with these plasmids
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions, and then incubated in DMEM containing 10%
FBS for 24 h followed by the application of Am80.2.3. Western blot analysis
The cells were lysed with 150 mM NaCl, 50 mM Tris–HCl (pH
7.5), 1% Nonidet P-40, 0.5% sodium deoxycholic acid, and Complete
Protease Inhibitor Cocktail Tablets (Roche), and the protein was
then isolated as previously described [15,16]. The protein content
was determined with the Bio-Rad Bradford protein assay. Seventy
micrograms of protein were separated by SDS–PAGE, transferred to
a PVDF membrane and analyzed by Western blotting using stan-
dard protocols. The membranes were blocked with 5% milk in TTBS
for 2 h at room temperature, and incubated overnight at 4 C using
following primary antibodies: 1:500 rabbit anti-KLF5 (Santa Cruz),
1:500 rabbit anti-RARa (Santa Cruz), 1:800 rabbit anti-phospho-
p38 (Cell Signaling), 1:1000 rabbit anti-p38 (Cell Signaling),
1:200 rabbit anti-phospho-Akt1/2/3 (Santa Cruz), 1:500 mouse
anti-Akt (Santa Cruz), and 1:1000 mouse anti-b-actin (Santa Cruz),1:400 mouse anti-HA (Santa Cruz). The membranes were then
incubated for 1 h at room temperature with a 1:5000 dilution of
anti-rabbit/horseradish peroxidase or anti-mouse/horseradish per-
oxidase (Santa Cruz Biotechnology) and developed with the
Chemiluminescence Plus Western blot analysis kit (Santa Cruz).
2.4. Co-immunoprecipitation assays
Co-immunoprecipitation was performed as described previ-
ously [17]. Brieﬂy, cell extracts were ﬁrst pre-cleared with 20 ll
of protein A-agarose (50% v/v). The supernatants were immunopre-
cipitated with 2 lg of anti-phosphoserine, anti-KLF5 or anti-RARa
antibodies for 1 h at 4 C, followed by incubation with protein A-
agarose overnight at 4 C. Protein A-agarose–antigen–antibody
complexes were collected by centrifugation at 12000 rpm for
20 s at 4 C. The pellets were washed four times with 500 ll IPH
buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5%
Nonidet P-40, 0.1 mM PMSF), for 20 min each time at 4 C. Bound
proteins were resolved by SDS–PAGE, followed by Western blot-
ting with the anti-RARa or anti-KLF5 antibodies. The experiments
were replicated three times at least.
2.5. Balloon injury model
Animals were anesthetized with urethane, 600 mg/kg i.p. The
thoracic-abdominal artery was de-endothelialized as described
previously [16]. In brief, the catheter was advanced from the left
common carotid artery down to the level of the renal arteries three
times with a 2F Fogarty catheter (Baxter, McGaw Park, IL). To attain
a constant degree of vessel wall injury for each of the animals, we
kept the diameter of the balloon and the resistance during with-
drawal constant and the same for each of the animals. All proce-
dures were performed by a single operator. After balloon injury,
the ligatures and catheter were then removed, the external carotid
artery was ligated, and the incision closed. The Am80 was admin-
istrated orally at a dose of 1 mg kg1 d1 beginning 1 day before
balloon injuring and continuing for 3 days or 14 days thereafter.
On days 3 and 14 after injury and administration of Am80 orally,
the animals were killed with an overdose of pentobarbital
(200 mg/kg), and the thoracic-abdominal artery was collected for
protein isolation and co-immunoprecipitation (Co-IP) assay.2.6. Statistical analysis
Results are expressed as means ± S.D., and an analysis of vari-
ance with Bonferroni’s test was used for the statistical analysis of
multiple comparisons of data. P-values less than 0.05 were consid-
ered statistically signiﬁcant.
3. Results
3.1. Am80 induces RARa expression and inhibits KLF5 expression in
VSMCs
We ﬁrst identiﬁed the speciﬁcity of anti-KLF5 antibody by over-
expressing HA-tagged KLF5 in cultured VSMCs. Western blot result
showed that anti-HA and anti-KLF5 antibodies detected recombi-
nant HA-tagged KLF5 at the predicted molecular mass, which
proved the speciﬁcity of anti-KLF5 antibody (Fig. 1A). To examine
the potential role of RARa and KLF5 in Am80 signaling and func-
tion, we ﬁrst examined the effect of Am80 on the expression of
KLF5 and RARa by Western blot analysis. As shown in Fig. 1B,
Am80 dose- and time-dependently induced the expression of
RARa. Exposure of VSMCs to Am80 (2 lmol/L) for 12 h signiﬁcantly
induced RARa expression, and the level of RARa increased by
Fig. 1. Expression of KLF5 and RARa in cultured VSMCs treated with Am80. (A)
Identiﬁcation of anti-KLF5 antibody. VSMCs were transiently transfected with
pMT3-KLF5 constructs encoding HA-tagged KLF5, and lysates were analyzed by
immunoblot analysis, using anti-KLF5 antibody and anti-HA antibody. (B) Rat
VSMCs were starved for 24 h and then treated with Am80 for various times or at
different doses. Cells were collected and Western blotting was performed using
anti-RARa and anti-KLF5 antibodies to examine the expression of RARa and KLF5,
respectively. b-Actin was used as a control for equal protein loading.
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Am80 in dose- and time-dependent manners. These results
suggest that RARa and KLF5 play a role in Am80 signaling and
function.
3.2. Am80 inhibits the interaction between KLF5 and RARa
Because KLF5 is known to physically bind to RARa [8,9], we
sought to examine if Am80 could affect the interaction between
KLF5 and RARa. To do this, we performed a co-immunoprecipita-
tion (Co-IP) assay by using crossing Co-IP. Treating cells with
Am80 for 0.5 and 1 h signiﬁcantly reduced RARa levels in precipi-
tates pulled down with anti-KLF5 antibody (Fig. 2A). Likewise,
Am80 also reduced levels of co-immunoprecipitated KLF5 pulled
down with anti-RARa antibody (Fig. 2A). We then tested whether
orally administered Am80 would reduce the interaction between
KLF5 and RARa within rat vascular wall. The injured arteries
caused by balloon were harvested at 3 and 14 days following in-
jury, and protein extracts were prepared and subjected to Co-IP as-Fig. 2. Am80 inhibits the interaction between KLF5 and RARa at the cellular and tissue l
then treated with Am80 for the indicated times. Cells were then harvested, and cell extra
indicated (IP). The precipitates were analyzed by Western blot analysis (WB). (B) Total pr
with Am80 for 3 or 14 days and untreated with Am80 (model) and uninjured right com
immunoprecipitation for interaction between KLF5 and RARa.say. We found that the Am80-administered group showed
signiﬁcantly less interaction between KLF5 and RARa than the con-
trol and model groups (Fig. 2B). Apparently, Am80 inhibits the
association of KLF5 with RARa at the cellular and tissue levels.
3.3. Am80 inhibits the interaction between KLF5 and RARa by inducing
KLF5 dephosphorylation
To understand whether the change in KLF5 phosphorylation is
responsible for Am80-induced suppression of interaction between
KLF5 and RARa, we detected the levels of phospho-KLF5 in VSMCs
treated with Am80. As shown in Fig. 3A, Am80 stimulation rapidly
induced dephosphorylation of KLF5 within 30 min. KLF5 phosphor-
ylation reached a minimum between 30 and 60 min and returned
to nearly basal levels after 2 h. Further, it is known that activation
of PI3K/Akt and p38 MAPK signaling is crucial for many fundamen-
tal cellular processes. To determine whether activation of PI3K and
p38 MAPKmediates KLF5 dephosphorylation induced by Am80, we
examined the levels of phospho-Akt and phospho-p38 by Western
blotting using phospho-speciﬁc antibodies. Fig. 3B shows that
Am80 time-dependently increased phospho-Akt level but de-
creased phospho-p38 level without affecting the levels of total
Akt and total p38. These results demonstrate that the PI3K/Akt
and p38 MAPK signaling play a key role in Am80-induced dephos-
phorylation of KLF5 in VSMCs. It has been reported that KLF5 DNA
binding domain (DBD) was sufﬁcient for its interaction with RARa
[18]. To further demonstrate that phosphorylation of the DBD of
KLF5 is important for its interaction with RARa, we mutated two
phosphorylation sites (P8, S406A and P9, S432A) within the DBD
of KLF5 and examined the signiﬁcance of these two sites for KLF5
interaction with RARa. We found that the interaction between
KLF5 and RARa was reduced to half when the serine in the poten-
tial phosphorylation site P8 (S406A) was mutated to alanine. Am80
treatment could not decrease the interaction between KLF5 and
RARa (Fig. 3C). Compared with the S406A mutant, the S432A
mutant had little effect on the interaction between KLF5 and RARa.
These results demonstrated that phosphorylation site P8 (S406A) is
important for the interaction between these two proteins.3.4. Akt inhibitor LY294002 prevents Am80-induced
dephosphorylation of KLF5
Since Am80 treatment leads to Akt phosphorylation, we
decided to test whether activated Akt is involved in Am80-inducedevels. (A) Cultured VSMCs were growth-arrested by serum deprivation for 24 h and
cts were subjected to immunoprecipitation with anti-KLF5 or anti-RARa antibody as
otein was isolated from balloon-injured left common carotid arteries of rats treated
mon carotid arteries (control). Then protein from each group was analyzed by co-
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sion of the interaction between KLF5 and RARa in VSMCs. The ef-
fects of Akt inhibitor LY294002 on Am80-induced KLF5
dephosphorylation and the interaction between KLF5 and RARa
in VSMCs were detected. As shown in Fig. 4A, LY294002 almost
completely blocked Am80-induced Akt phosphorylation and
Am80-induced KLF5 dephosphorylation, without affecting the
expression of KLF5 and Akt. Fig. 4B shows that Am80-induced sup-
pression of interaction between KLF5 and RARa was reversed by
treatment with LY294002, suggesting that activation of PI3K/Akt
pathway is involved in Am80-induced KLF5 dephosphorylation.Fig. 3. Am80 stimulates KLF5 dephosphorylation by activating PI3K/Akt signaling and in
for different times, and then subjected to Western blot analysis. (A) Cell extracts wer
antibody to KLF5. (B) Western blotting was performed on cell lysates using phospho-spe
Blots for total protein are also shown (Akt or p38). (C) Nine potential phosphorylation sit
Gln (PQ) and Pro/Ser (PS) clusters are indicated. PMT-KLF5 or PMT-KLF5 S406A (P8 mu
Interaction between KLF5 and RARa was examined by co-immunoprecipitation and We
Fig. 4. Effects of the Akt inhibitor LY294002 on Am80-induced KLF5 dephosphorylatio
exposure to Am80 (2 lmol/L) for 1 h. (A) The phospho-KLF5 and phospho-Akt were assess
immunoprecipitation and Western blot analysis with the indicated antibodies.3.5. Am80 inhibits KLF5 phosphorylation via p38 pathway
Because Am80-induced suppression of the interaction between
KLF5 and RARawas accompanied by the prominent decrease of the
phospho-KLF5 and the phospho-p38 levels, this prompted us to
examine whether the p38 MAPK pathway is involved in Am80-in-
duced KLF5 dephosphorylation. First, we tested the effect of consti-
tutively active p38 kinase MKK6b on KLF5 phosphorylation. As
shown in Fig. 5A, infection of VSMCs with MKK6b substantially
prevented the KLF5 dephosphorylation induced by Am80, strongly
suggesting that the activation of p38 MAPK pathway stimulateshibiting p38 MAPK signaling. Cultured VSMCs were incubated with 2 lmol/L Am80
e immunoprecipitated with antibody to phosphoserine and immunoblotted with
ciﬁc antibodies to detect phosphorylated Akt and phosphorylated p38, respectively.
es are labeled P1-P9. The amino acid positions of the three zinc ﬁngers and Pro/Ala/
tant) or PMT-KLF5 S432A (P9 mutant) were transfected into VSMCs, respectively.
stern blot analysis with the indicated antibodies as described above.
n. VSMCs were pretreated with Akt inhibitor LY294002 (20 lmol/L) for 2 h before
ed as described above. (B) Interaction between KLF5 and RARawas examined by co-
Fig. 5. Am80 inhibits KLF5 phosphorylation and its interaction with RARa by repressing p38 MAPK signaling in VSMCs. (A) Cultured VSMCs were transfected with
constitutively active p38 kinase construct MKK6b for 24 h, and then stimulated with Am80 (2 lmol/L) for 1 h. Cells were harvested and immunoprecipitating was performed
to detect the phospho-KLF5. The empty vector (pSV) was used as a control. (B) Cultured VSMCs were pretreated with p38 kinase inhibitor SB203580 (20 lmol/L) for 2 h before
exposure to Am80 (2 lmol/L) for 1 h. The interaction between KLF5 and RARawas assessed by co-immunoprecipitating andWestern blotting with the indicated antibodies as
described above.
X.-h. Zhang et al. / FEBS Letters 583 (2009) 1231–1236 1235KLF5 phosphorylation in VSMCs. To further determine the poten-
tial role of p38 MAPK signaling pathway in regulating the interac-
tion between KLF5 and RARa, VSMCs were pretreated for 2 h with
SB203580 (20 lmol/L), a speciﬁc inhibitor for p38 kinase, and then
stimulated with Am80 (2 lmol/L) for 1 h. As shown in Fig. 5B,
SB203580 further attenuated the interaction between KLF5 and
RARa, i.e., RARa level or KLF5 level in precipitates pulled down
with anti-KLF5 antibody or anti-RARa antibody, respectively, was
signiﬁcantly less than Am80-induced those alone. Taken together,
these ﬁndings clearly indicate that Am80 inhibits KLF5 phosphor-
ylation and its interaction with RARa by blocking activation of
p38 pathway.
3.6. Activation of the PI3K/Akt pathway is involved in Am80-triggered
p38 inhibition
Previous studies have reported that there are cross-talks be-
tween the PI3K/Akt pathway and the p38 MAPK pathway in several
cell types with different stimuli [19,20]. We then tested whether
cross-talk between the PI3K/Akt and p38 MAPK pathway is in-
volved in the Am80-induced KLF5 dephosphorylation in VSMCs.
We inhibited the PI3K/Akt pathway and the p38 MAPK pathway
using LY294002 and SB203580, respectively. As shown in Fig. 6A,
inhibiting Akt phosphorylation by LY294002 abrogated Am80-in-
duced inhibition of p38 phosphorylation. In contrast, inhibitionFig. 6. PI3K/Akt activation leads to the inhibition of p38 phosphorylation. Cultured
VSMCs were pretreated with 20 lmol/L LY294002 (A) or 20 lmol/L SB203580 (B)
for 2 h and then stimulated with 2 lmol/L Am80 for 1 h. Western blotting was
performed by using antibodies against phospho-p38 (A) and phospho-Akt (B),
respectively. Total Akt and total p38 were also detected by Western blotting using
the corresponding antibodies.of p38 by the p38 kinase inhibitor SB203580 had no effect on
Akt phosphorylation induced by Am80 (Fig. 6B). These data suggest
that the activation of PI3K/Akt signaling is responsible for the inhi-
bition of the p38 MAPK signaling by Am80, and that p38 MAPK is a
downstream target of PI3K/Akt pathway in response to Am80 in
VSMCs.4. Discussion
The present study demonstrates that Am80 induces KLF5
dephosphorylation and inhibits the interaction of KLF5 with RARa
via the PI3K/Akt pathway and p38 MAPK pathway in VSMCs. First,
we showed that Am80 signiﬁcantly induces RARa expression and
inhibits KLF5 expression and its interaction with RARa at the cel-
lular and tissue level. Furthermore, we established that this action
of Am80 is mediated by activating the PI3K/Akt pathway and
inhibiting the p38 MAPK pathway. This study is the ﬁrst report
to delineate the molecular mechanism by which Am80 inhibits
the interaction between KLF5 and RARa.
The KLF family of transcription factors has received widespread
attention due to roles in various biological events, among which
KLF5 is involved in the cardiovascular remodeling in response to
stress. Because KLF5 plays critical roles in regulating cellular pro-
cesses, the mechanisms regulating its activity have been the sub-
ject of intense interest. Several recent studies have shown that
regulation of KLF5 activity can occur on multiple levels, including
interaction with cofactors and modiﬁcations (e.g., phosphorylation
and acetylation), which results in additional regulation affecting
the speciﬁcity of actions of KLF5. For example, KLF5 activity is in-
creased via its interaction with the coactivator/acetylase p300
[21], and deacetylase (histone deacetylase 1 [HDAC1]) negatively
regulates the transcriptional activity of KLF5 via direct interaction
as well as inhibition of its interaction with p300 [22]. Previous
study has also demonstrated that KLF5 associates with the p50
subunit of nuclear factor jB (NF-jB) in phorbol ester-induced
pathologic conditions in SMCs and that this mechanism is respon-
sible for the delayed yet persistent activation of PDGF-A chain by
KLF5 after the initial activation by Egr-1. Previous study demon-
strates KLF5 interacts with RARa, and RARa agonist suppresses
KLF5 function whereas RARa antagonist activates KLF5. These
studies suggest that the interaction of KLF5 with RARa may
provide a novel means of regulating KLF5 activity. Indeed, a recent
evidence shows that Am80 can inhibit the transcriptional activity
of KLF5 [9]. Given these ﬁndings, we think that the interaction of
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in various cellular processes. Importantly, Nagai proved that Am80
inhibits the interaction of KLF5 with RARa [9], however, the molec-
ular mechanism of this inhibitory effect by Am80 is unclear.
Protein phosphorylation has been an important mechanism by
which a transcription activator recruits coactivators, such as phos-
phorylation of cAMP response element-binding protein (CREB) at
Ser133 leading to the recruitment of CREB-binding protein (CBP)
[23], phosphorylation of KLF5 at the CBP interaction region
enhancing its interaction with CBP and its transactivation function
[24]. We hypothesized that the Am80-induced repression of the
interaction of KLF5 with RARa may be associated with the KLF5
dephosphorylation by Am80. Thus, we ﬁrst examined the level of
phospho-KLF5 in VSMCs stimulated by Am80, and we found that
Am80 rapidly and strongly induced KLF5 dephosphorylation in a
time-dependent manner in rat VSMCs. Furthermore, Am80-in-
duced KLF5 dephosphorylation is accompanied by the repression
of the interaction between KLF5 and RARa. We demonstrated that
phosphorylation site P8 (S406A) is important for the interaction
between KLF5 and RARa. Previous studies have demonstrated that
the PI3K/Akt pathway and the p38 MAPK pathway play an impor-
tant role in VSMC proliferation and vascular remodeling. To further
deﬁne the signaling pathways leading to Am80-induced KLF5
dephosphorylation, we examined the effects of Akt inhibitors and
p38 inhibitors on KLF5 dephosphorylation induced by Am80. Inhi-
bition of Akt by LY294002 blocked Am80-induced Akt phosphory-
lation and KLF5 dephosphorylation, whereas inhibition of p38
kinase by SB203580 further suppressed the interaction of KLF5
with RARa via inhibiting p38 phosphorylation. In addition, we ob-
served that the KLF5 dephosphorylation induced by Am80 is inhib-
ited by infection of adenovirus expressing constitutively active
MAPK kinase MKK6b. These results strongly suggest that Am80 in-
duces KLF5 dephosphorylation by activating PI3K/Akt signaling,
and inhibits KLF5 phosphorylation by blocking p38 signaling.
Moreover, we found that inhibition of Akt by LY294002 abolished
inhibition of p38 phosphorylation by Am80, further demonstrating
that p38 is downstream of Akt signaling. Importantly, these results
are consistent with the recent reports that there is cross-talk be-
tween the PI3K/Akt and ERK1/2 pathways and that constitutively
active Akt can negatively regulate the Ras/Raf/MEF/ERK1/2 cascade
and inactivation of the kinase Raf [25].
In summary, we have found that the PI3K/Akt pathway, which
negatively regulates the p38 MAPK pathway, mediates the
Am80-induced KLF5 dephosphorylation, subsequently leading to
the inhibition of the interaction of KLF5 with RARa. These results
provide novel insight not only into the molecular mechanism of
the inhibitory effect by Am80 through inducing KLF5 dephospho-
rylation but also a speciﬁc therapeutic target for vascular remodel-
ing in diseases such as atherosclerosis. Further studies need to
address the precise mechanism by which the PI3K/Akt-p38-KLF5
pathway regulates the speciﬁc gene expression.Acknowledgments
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